Naloxegol (Greater Than 12.5 mg)/Moderate CYP3A4 Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Your other medicine may slow down how quickly your body processes naloxegol.

What might happen:

The amount of naloxegol in your blood may increase, which may increase your risk of experiencing withdrawal symptoms from your pain medication.

What you should do about this interaction:

Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Let your doctor know if you experience any signs of withdrawal from your pain medication such as sweating, chills, diarrhea, stomach pain, anxiety, irritability, yawning, increased tear production, runny nose, or gooseflesh skin. If you are taking methadone, you may also experience abdominal pain and/or diarrhea. Let your doctor know if these occur. Your doctor may want to change the dose of your naloxegol.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Movantik (naloxegol) US prescribing information. AstraZeneca Pharmaceuticals LP April, 2020.
  • 2.US FDA Center for Drug Evaluation and Research. Naloxegol Clinical Pharmacology and Biopharmaceutics Review. Application number 204760Orig1s000. available at: Pharm.pdf July 25, 2014.
  • 3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
  • 4.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2019..

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.